Literature DB >> 25124969

Dosage individualization in children: integration of pharmacometrics in clinical practice.

Wei Zhao1, Stéphanie Leroux, Evelyne Jacqz-Aigrain.   

Abstract

BACKGROUND: Children are in a continuous and dynamically changing state of growth and development. A thorough understanding of developmental pharmacokinetics (PK) and pharmacodynamics (PD) is required to optimize drug therapy in children. DATA SOURCES: Based on recent publications and the experience of our group, we present an outline on integrating pharmacometrics in pediatric clinical practice to develop evidence-based personalized pharmacotherapy.
RESULTS: Antibiotics in septic neonates and immunosuppressants in pediatric transplant recipients are provided as proof-of-concept to demonstrate the utility of pharmacometrics in clinical practice. Dosage individualization based on developmental PK-PD model has potential benefits of improving the efficacy and safety of drug therapy in children.
CONCLUSION: The pharmacometric technique should be better developed and used in clinical practice to personalize drug therapy in children in order to decrease variability of drug exposure and associated risks of overdose or underdose.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25124969     DOI: 10.1007/s12519-014-0493-x

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  59 in total

1.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 2.  The use of unlicensed and off-label medicines in the neonate.

Authors:  Sharon Conroy; John McIntyre
Journal:  Semin Fetal Neonatal Med       Date:  2005-01-25       Impact factor: 3.926

3.  Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.

Authors:  Wei Zhao; May Fakhoury; Véronique Baudouin; Anne Maisin; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Ther Drug Monit       Date:  2011-12       Impact factor: 3.681

Review 4.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients.

Authors:  Wei Zhao; May Fakhoury; Véronique Baudouin; Thomas Storme; Anne Maisin; Georges Deschênes; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

Review 6.  Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities.

Authors:  Evelyne Jacqz-Aigrain
Journal:  Early Hum Dev       Date:  2011-01-26       Impact factor: 2.079

7.  Standard dosing of tacrolimus leads to overexposure in pediatric renal transplantation recipients.

Authors:  Joshua Y Kausman; Bhumik Patel; Stephen D Marks
Journal:  Pediatr Transplant       Date:  2008-05

8.  A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates.

Authors:  Roosmarijn F W De Cock; Karel Allegaert; Catherine M T Sherwin; Elisabet I Nielsen; Matthijs de Hoog; Johannes N van den Anker; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

Review 9.  The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.

Authors:  Dennis A Hesselink; Rachida Bouamar; Laure Elens; Ron H N van Schaik; Teun van Gelder
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

10.  Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.

Authors:  Adriana Tremoulet; Jennifer Le; Brenda Poindexter; Janice E Sullivan; Matthew Laughon; Paula Delmore; Andrea Salgado; Sandy Ian-U Chong; Chiara Melloni; Jamie Gao; Daniel K Benjamin; Edmund V Capparelli; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.938

View more
  7 in total

1.  Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

Authors:  Stéphanie Leroux; Evelyne Jacqz-Aigrain; Valérie Biran; Emmanuel Lopez; Doriane Madeleneau; Camille Wallon; Elodie Zana-Taïeb; Anne-Laure Virlouvet; Stéphane Rioualen; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.

Authors:  Wei Zhao; Daolun Zhang; Thomas Storme; André Baruchel; Xavier Declèves; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2015-09-05       Impact factor: 4.335

3.  A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Authors:  Stéphanie Leroux; Jean-Michel Roué; Jean-Bernard Gouyon; Valérie Biran; Hao Zheng; Wei Zhao; Evelyne Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

4.  Optimal Dosing of Ceftriaxone in Infants Based on a Developmental Population Pharmacokinetic-Pharmacodynamic Analysis.

Authors:  Ya-Kun Wang; Yue-E Wu; Dian-Ping You; Wei Zhao; Xue Li; Li-Yuan Tian; Muhammad Wasim Khan; Bo-Hao Tang; Hai-Yan Shi; Yi Zheng; Guo-Xiang Hao; John van den Anker
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 5.  Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.

Authors:  Frederique Rodieux; Melanie Wilbaux; Johannes N van den Anker; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 6.  Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 5.577

Review 7.  How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians.

Authors:  Eric Vermeulen; John N van den Anker; Oscar Della Pasqua; Kalle Hoppu; Johanna H van der Lee
Journal:  J Pharm Pharmacol       Date:  2016-09-27       Impact factor: 3.765

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.